Recent Comments

Comment RSS

Hormonal Therapy News and Research RSS Feed - Hormonal Therapy News and Research

Hormonal Therapy is treatment that adds, blocks, or removes hormones. For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels. To slow or stop the growth of certain cancers (such as prostate and breast cancer), synthetic hormones or other drugs may be given to block the body’s natural hormones. Sometimes surgery is needed to remove the gland that makes a certain hormone. Also called endocrine therapy, hormone therapy, and hormone treatment.

Comprehensive report on world cancer therapies market

20. November 2009 01:37
Research and Markets (http://www.researchandmarkets.com/research/4b82d8/cancer_therapies) has announced the addition of the "Cancer Therapies - Global Market Opportunities" report to their offering. [More]

Breastcancer.org opposes proposed new guidelines for mammograms

19. November 2009 05:54
"The recommendation to change breast screening is a huge step backwards," says Dr. Marisa Weiss, a leading breast oncologist and founder and president of Breastcancer.org. [More]

OncoVista Innovative Therapies' AdnaTest BreastCancer and EMT1/StemCell products evaluated in German hospitals

11. November 2009 03:59
OncoVista Innovative Therapies, Inc. reported today that two of its proprietary products, the AdnaTest™ BreastCancer and AdnaTest EMT1/StemCell, were evaluated in Germany by the Departments of Gynecology and Obstetrics and Internal Medicine (Cancer Research) at University Hospital Essen, University of Duisburg-Essen and the Department of Gynecology and Obstetrics, University Hospital of Tuebingen. [More]

Decision Resources forecasts sales of HER2-targeting agents to grow by 3.3% per year

9. November 2009 08:41
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2008, human epidermal growth factor receptor 2 (HER2) targeting therapies -- which include Roche/Chugai's Herceptin and GlaxoSmithKline/Nippon Kayaku's Tykerb/Tyverb -- were the highest-selling drug class in breast cancer treatment. [More]

Posted in: Women's Health News | Pharmaceutical News

Tags: , , , , ,

Combination therapy before prostate removal may prevent recurrence of cancer

4. November 2009 23:14
Researchers in the Oregon Health & Science University Knight Cancer Institute and the Portland Veterans Affairs Medical Center have found a combination of radiation therapy and chemotherapy given before prostate removal is safe and may have the potential to reduce cancer recurrence and improve patient survival. [More]

Blood vessels good indicators of prostate cancer behavior

4. November 2009 00:10
A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed? [More]

Posted in: Men's Health News

Tags: , , , , , , , ,

Report on breast cancer and the therapy involved

27. October 2009 06:27
The Breast Cancer Disease and Therapy Review provides incidence and one-year and five-year prevalence numbers and percentages for major countries worldwide. Information on diagnosis, staging (using the TNM system), and an overview of treatments are also provided. [More]

Posted in: Women's Health News

Tags: , , ,

American Recovery and Reinvestment Act funds to support research in numerous health areas

14. October 2009 02:27
As part of the $5 billion in grants announced by President Obama, the National Institutes of Health has granted Kaiser Permanente more than $54 million over two years through the American Recovery and Reinvestment Act to conduct health research on a multitude of critical public and clinical health areas. [More]

Kaiser Permanente receives $54 million grant from NIH to conduct health research

14. October 2009 00:07
As part of the $5 billion in grants announced by President Obama, the National Institutes of Health has granted Kaiser Permanente more than $54 million over two years through the American Recovery and Reinvestment Act to conduct health research on a multitude of critical public and clinical health areas. [More]

HRT may increase urinary incontinence in postmenopausal women

7. October 2009 02:01
Grappling with the risks and benefits of hormone replacement therapy (HRT) is nothing new for postmenopausal women. Researchers have now added more fuel to the fire, with evidence that HRT could play a role in incontinence. [More]

Results of IES presented at ECCO

23. September 2009 02:50
Pfizer Inc today announced new, longer-term data from the Intergroup Exemestane Study (IES) showing that women who switched to AROMASIN® (exemestane tablets) after taking tamoxifen for two to three years experienced a significant reduction (18%) in the risk of disease-free survival (DFS) events. In addition, IES showed that AROMASIN prolonged overall survival (OS) in the ER+/unknown population with a 14% reduction in the risk of dying. These results demonstrate that the benefits of treatment are maintained in long term follow-up. These results were presented at the joint ECCO 15/ESMO 34 meeting in Berlin, Germany. [More]

Cryosurgery: Primary treatment option for prostate cancer

16. September 2009 09:44
After years of innovation and intensive research, a team of Binghamton University (BU) researchers working with Cell Preservation Services, Inc., Owego, NY has broken extraordinary new ground in the recognition of cryosurgery as a primary treatment option for prostate cancer. [More]

Phase 1 results of CTP-347 presented

14. September 2009 08:18
Concert Pharmaceuticals, Inc. announced today the presentation of Phase 1 data on CTP-347, a deuterium-modified analog of paroxetine for the treatment of hot flashes. Concert presented the results during a poster session at the American College of Clinical Pharmacology’s 38th Annual Meeting. [More]

Posted in: Drug Trial News

Tags: , , , , , , , , ,

Reportlinker's report analyzes the global market for cancer therapies

11. September 2009 03:15
Reportlinker.com announces that a new market research report is available in its catalogue. [More]

Increased risk of death for men with heart conditions undergoing RT with hormone therapy for prostate cancer

26. August 2009 01:42
Men with coronary artery disease-induced congestive heart failure or heart attack who receive hormone therapy before or along with radiation therapy for treatment of prostate cancer have an associated increased risk of death, according to a study in the August 26 issue of JAMA. [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.